OncoMatch/Clinical Trials/NCT06043674
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Is NCT06043674 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for chronic lymphocytic leukemia.
Treatment: Glofitamab · Obinutuzumab · Polatuzumab Vedotin · Atezolizumab · Tocilizumab · Pirtobrutinib — This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an antibody-drug conjugate) * Pirtobrutinib (a selective inhibitor of BTK) * Atezolizumab (a humanized immunoglobulin monoclonal antibody) * Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-CD20 bispecific antibody
No prior anti-CD20 bispecific antibody is allowed.
Cannot have received: antibody-drug conjugate (polatuzumab vedotin)
Exception: for patients in the polatuzumab vedotin-containing combination arm
No prior polatuzumab vedotin is allowed for patients in the polatuzumab vedotin-containing combination arm.
Cannot have received: BTK inhibitor (pirtobrutinib)
Exception: for patients in the pirtobrutinib-containing arm
No prior pirtobrutinib is allowed for patients in the pirtobrutinib-containing arm.
Cannot have received: anti-PD-L1 therapy (atezolizumab)
Exception: for patients in the atezolizumab-containing combination arm
No prior atezolizumab therapy is allowed for patients in the atezolizumab-containing combination arm.
Cannot have received: CAR-T cell therapy
Prior treatment with CAR T-cell therapy within 30 days before first study treatment administration.
Lab requirements
Blood counts
ANC > 1.0 x10^9/L (growth factor allowed), platelets > 30 x10^9/L (or > 50 x10^9/L for pirtobrutinib arm), hemoglobin > 8 g/dL (pirtobrutinib arm)
Kidney function
Creatinine < 2.0 x ULN or estimated CrCl > 50 ml/min
Liver function
Total bilirubin < 1.5 X ULN (up to 3.0 X ULN for Gilbert's or resolving autoimmune hemolytic anemia); AST/ALT < 3.0 X ULN (or < 5.0 X ULN with documented liver involvement by lymphoma)
Cardiac function
Adequate coagulation (aPTT/PT/INR ≤ 1.5 x ULN); no NYHA Class III/IV heart failure; no recent MI/unstable angina; LVEF > 40% for pirtobrutinib arm
See cohort-specific organ and marrow function requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Winship Cancer Institute at Emory University · Atlanta, Georgia
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
- The University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
- The Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify